Another study stratified tumor samples on baseline PD-L1 levels and found that the PD-L1+ subgroup had decreased PD-L1 expression following RAF/MEK inhibitor treatment, possibly due to the overall absence of tumor-infiltrating lymphocytes in progressed samples or a switch to other resistance pathways, such as immunosuppressive cytokine release [51]. The gene discussed is MAP2K7; the disease is neoplasm.